Find Therapeutics has secured CA$10 million (approximately $7.4 million) in funding to continue advancing tasronetide, its lead candidate for boosting myelin repair in people with multiple sclerosis (MS). The Series A extension financing round follows the completion of a Phase 1 trial in healthy volunteers, in which tasronetide…
myelin repair
Evogene and Unravel Biosciences are collaborating to develop a new class of therapies targeting myelin repair in multiple sclerosis (MS) and similar disorders. By combining two distinct artificial intelligence platforms, the companies hope to create the first treatment capable of…